Respiratory & Immunology is one of AstraZeneca’s three therapy areas and is a key growth driver for the Company.
AstraZeneca is an established leader in respiratory care, and its inhaled and biologic medicines reached more than 53 million patients in 2019. Building on a 50-year heritage, the Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death. The Company’s early respiratory research is focused on emerging science involving immune mechanisms, lung damage and abnormal cell repair processes in disease and neuronal dysfunction.
To learn more, select one of the links below:
For US HCPs: https://medicalinformation.astrazeneca-us.com/
For non-US HCPs: www.azmedx.com
Adverse events should be reported here: https://aereporting.astrazeneca.com/
VPM ID: Z4-28883 Prepared: November 2020